ReviewThe Korean journal of internal medicine2018
Updated treatment strategies for intestinal Behçet's disease.
Review in The Korean journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).Gut and liver · 2023Trial
- Effectiveness and Tolerability of Anti-Tumor Necrosis Factor Alpha Therapy in Refractory Intestinal Behçet's Disease: A Large Single-Center Study.Gut and liver · 2026Article
- Successful Remission of Refractory Oral Ulcers Treated with Low-Dose Thalidomide and Colchicine: A Case Report.Reports (MDPI) · 2026Article
- Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.BMC gastroenterology · 2023Observational
- Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study.The Korean journal of internal medicine · 2023Article
- Article
- Efficacy of Calcineurin Inhibitors for Induction of Remission in Intestinal Behçet's Disease.Crohn's & colitis 360 · 2022Article
- Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.BMC gastroenterology · 2022Article
- Behcet's Disease: An In-Depth Review about Pathogenesis, Gastrointestinal Manifestations, and Management.Inflammatory intestinal diseases · 2021Review
- C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease.BMC gastroenterology · 2021Article
- Behçet Disease: An Update for Dermatologists.American journal of clinical dermatology · 2021Review
- Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach.Frontiers in medicine · 2021Review
- Experimental Therapeutic Solutions for Behcet's Disease.Journal of experimental pharmacology · 2021Review
- [Esophageal Involvement of Behcet's Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2020Article
- Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet's disease.Zeitschrift fur Rheumatologie · 2020Article
- The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.Internal medicine (Tokyo, Japan) · 2020Article
- Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?Intestinal research · 2020Article
- Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet's disease.Scientific reports · 2019Article
- Update on the treatment of Behçet's syndrome.Internal and emergency medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.